CMS Finalizes Narrower GLOBE Drug Pricing Model; Concerns for Innovation
CMS has finalized its Global Benchmark for Efficient Drug Pricing (GLOBE) Model, establishing a mandatory Medicare demonstration that uses international drug prices to calculate manufacturer rebates for certain physician-administered medicines. Although the final rule substantially narrows the original proposal, the Biotechnology Innovation Organization (BIO), and state partners like MichBio, continue to oppose the approach, warning that it could weaken investment in new treatments and U.S. biotechnology competitiveness.
Announced September 30, GLOBE targets selected drugs covered by Original Medicare Part B, including treatments administered in clinical settings for cancer and autoimmune diseases. CMS says the model will test whether international pricing benchmarks can lower Medicare spending and patients’ out-of-pocket costs while maintaining quality of care. It will cover randomly selected geographic areas representing approximately 25% of beneficiaries with Original Medicare as their primary coverage.
The rule becomes effective November 30, 2026. Voluntary manufacturer submission of international pricing data begins January 1, 2027, followed by a five-year performance period from April 1, 2027, through March 31, 2032. Rebate invoicing and reconciliation extend through March 2034.
The model focuses on eligible single-source drugs and sole-source biologics in seven therapeutic categories, with an initial annual Part B spending threshold exceeding $100 million. Its benchmark framework draws on 19 economically comparable countries, using a default based on the lowest adjusted country price or an alternative incorporating voluntarily submitted manufacturer net-pricing data. Manufacturers bear the rebate obligation; providers retain the existing average-sales-price-based payment framework. Eligible patients may receive lower coinsurance beginning April 2027.
Several exclusions distinguish the final rule from the proposal. CMS added protections for orphan-only drugs, plasma-derived products, and products listed by FDA as approved cellular and gene therapies. Other exclusions address generic and biosimilar competition and drugs with Medicare-negotiated maximum fair prices in effect. The orphan-only provision applies when all approved indications are for designated rare diseases or conditions; an orphan designation alone does not establish eligibility.
CMS now estimates $440 million in net Medicare Part B savings over the seven-year payment period. BIO’s analysis contrasts that figure with approximately $11.9 billion projected for the proposal, underscoring the final model’s reduced reach. BIO also cautions that a voluntary most-favored-nation agreement does not automatically exempt a manufacturer. CMS instead identifies model-overlap waivers, including through GENEROUS, as a mechanism for addressing participation.
Despite the narrower scope, BIO’s opposition remains firm. In a statement distributed to state association partners, President and CEO John Crowley said finalizing GLOBE “threatens the innovation ecosystem that makes new treatments and cures possible.” He argued that mandatory government price-setting would not resolve underlying healthcare cost pressures or access barriers, and could weaken American leadership as China expands its life sciences investments.
For Michigan companies, the immediate task is to assess product eligibility, potential rebate exposure, and international pricing-data requirements. New exclusions may shield some portfolios, but companies pursuing additional indications should consider whether those changes could affect eligibility. For emerging developers, uncertainty about future net revenues could influence licensing negotiations, financing, and pipeline priorities. Those are potential business implications rather than established outcomes, making implementation details and evidence of patient access especially important to monitor.
